ULTRAGENYX PHARMACEUTICAL INC. - COMMON STOCK

GeneTx and Ultragenyx Provide Preliminary Update on Phase 1/2 Clinical Study of GTX-102 in Canada and U.K. Patients with Angelman Syndrome

05 Jan 2022 07:00:01 By Nasdaq GlobeNewswire

Ultragenyx to Present at 40th Annual JP Morgan Healthcare Conference

03 Jan 2022 15:01:00 By Nasdaq GlobeNewswire

GeneTx and Ultragenyx Announce Presentations at Upcoming 2021 FAST Global Summit & Gala

01 Dec 2021 15:30:00 By Nasdaq GlobeNewswire

Ultragenyx Announces First Patient Dosed in Phase 1/2 Clinical Study of UX053, an mRNA Therapy for the Treatment of Glycogen Storage Disease Type III

01 Dec 2021 07:00:01 By Nasdaq GlobeNewswire

Ultragenyx to Present at Evercore 4th Annual HealthconX Conference

29 Nov 2021 15:40:38 By Nasdaq GlobeNewswire

Ultragenyx Announces Additional Positive Multi-Year Durability Data from Phase 1/2 AAV Gene Therapy Studies

29 Nov 2021 07:00:00 By Nasdaq GlobeNewswire

Ultragenyx Reports Third Quarter 2021 Financial Results and Corporate Update

02 Nov 2021 15:05:03 By Nasdaq GlobeNewswire

Ultragenyx to Host Conference Call for Third Quarter 2021 Financial Results and Corporate Update

26 Oct 2021 15:05:00 By Nasdaq GlobeNewswire

Ultragenyx to Present at Jefferies Gene Therapy/Editing Summit

25 Oct 2021 15:05:00 By Nasdaq GlobeNewswire

Ultragenyx Initiates Cyprus2+, a Pivotal Clinical Trial Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease

18 Oct 2021 07:00:01 By Nasdaq GlobeNewswire